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Abstract
Purpose The aim of the present study was to evaluate the
accuracy of hypodense regions in non-contrast-enhanced
cardiac computed tomography (unenhanced CT) to identify
nonviable myocardial scar tissue.
Methods Hypodense areas were visually identified in unen-
hanced CT of 80 patients in the left ventricular anterior,
apical, septal, lateral and inferior myocardium and CT den-
sity was measured in Hounsfield units (HU). Findings were
compared to 18F-fluorodeoxyglucose uptake by positron
emission tomography (FDG PET), which served as the
standard of reference to distinguish scar (<50 % FDG up-
take) from viable tissue (≥50 % uptake).
Results Visually detected hypodense regions demonstrated
a sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) of 74, 97, 84 and 94 %,
respectively. A receiver-operating characteristic (ROC)
curve analysis revealed a cutoff value of mean HU at
<28.8 for predicting scar tissue with an area under the curve
of 0.93 yielding a sensitivity, specificity, PPV and NPV of
94, 90, 67 and 99 %, respectively.
Conclusion Hypodense regions in unenhanced cardiac CT
scans allow accurate identification of nonviable myocardial
scar tissue.
Keywords Non-contrast coronary computed tomography
(NCCT) . Viability . Positron emission tomography (PET) .
Myocardial infarction . Computed tomography (CT)
Introduction
Non-contrast-enhanced cardiac computed tomography
(unenhanced CT) is increasingly being used for attenuation
correction of cardiac nuclear scans as it has been shown to
improve image quality as well as diagnostic [1] and prog-
nostic accuracy [2] of single photon emission computed
tomography (SPECT) myocardial perfusion imaging (MPI)
for the evaluation of coronary artery disease (CAD).
The use of unenhanced CT is likely to increase in the near
future not only due to the joint recommendation by the
Society of Nuclear Medicine and the American Society of
Nuclear Cardiology [3], but also facilitated by the increasing
availability of integrated SPECT/CT scanners. Similarly, the
use of unenhanced CT for cardiac risk assessment by coro-
nary calcium scoring is rapidly growing [4].
Unenhanced CT scans offer added diagnostic information
on top of attenuation correction and coronary calcium scoring
[4, 5] such as evaluation of pulmonary artery dimensions
reflecting pulmonary hypertension [6], clinically relevant inci-
dental findings [7, 8], left ventricular (LV) mass and volume [9]
and epicardial fat volume as a predictor of cardiac events [10].
A recent study has suggested a relation between hypodense
myocardial areas in unenhanced CT and fixed perfusion
defects on 99mTc-sestamibi SPECT [11]. However, 99mTc-
sestamibi SPECT is less accurate than 18F-fluorodeoxyglu-
cose positron emission tomography (FDG PET) for detecting
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hypoperfused but viable myocardium with the potential for
functional recovery after revascularization [12, 13]. Further-
more, in the latter study irreversible perfusion defects were
assessed visually rather than quantitatively, which is a major
limitation due to the high variability of visual assessment [12].
Therefore, the aim of the present study was to explore the
accuracy of hypodense LV areas in unenhanced CT for
identifying nonviable myocardial scar tissue using FDG
PET as the gold standard.
Materials and methods
Study population
The study population consisted of 80 consecutive patients
with angiographically proven CAD, who were referred for
viability evaluation by FDG PET. All patients included in the
present study routinely underwent low-dose unenhanced CT
scanning for calcium scoring and/or attenuation correction of
nuclear cardiac scanning. The need for written informed con-
sent was waived by the Institutional Review Board (Local
Ethics Committee) due to the retrospective nature of this study
with solely clinical data collection.
FDG PET image acquisition and analysis
The patients were advised to fast for at least 6 h before the PET
examination. After a standardized oral glucose load, 250MBq
of FDG were injected as previously reported [14, 15] accord-
ing to the recommendations of the American Society of Nu-
clear Cardiology [16]. One hour later images were acquired on
a Discovery (LS/RX) PET/CT scanner (GE Healthcare, Mil-
waukee, WI, USA). CT attenuation maps were used for atten-
uation correction as previously described [17, 18].
Reconstructions of acquired images were performed by using
attenuation weighted ordered subset expectation maximiza-
tion iterative reconstruction (2 iterations and 8 subsets).
FDG uptake polar maps were derived by using CardIQ
Physio software package (GE Healthcare, AW 4.4 or 4.6).
Regional FDG uptake in per cent of maximal uptake was
assessed in a polar plot representing five regions, i.e. anterior,
apical, septal, lateral and inferior LV wall. Nonviable tissue
was defined as regions with less than 50 % FDG uptake [19].
In order to account for differences in the definition of the FDG
uptake threshold to predict viability we have provided the
results for different thresholds, i.e. 30, 40, 50 and 60 %.
Unenhanced CT acquisition and analysis
Unenhanced CT scans covering the whole heart were per-
formed using prospective ECG-triggered sequential images as
previously reported in detail [5]. Briefly, CT scans were
obtained on a LightSpeed VCT scanner (General Electric
Medical Systems, Milwaukee, WI, USA) or high-definition
Table 1 Patient characteristics (n080)
Characteristic Value
Age, years (mean ± SD) 64.5±12.4
Male 74 (93 %)
BMI, kg/m2 (mean ± SD) 26.7±4.4
EF (%) 26.7±11.6
Cardiovascular risk factors
Hypertension 43 (54 %)
Dyslipidaemia 49 (61 %)
Smoking 48 (60 %)
Positive family history 17 (21 %)
Diabetes 21 (26 %)
History of CAD
Myocardial infarction 60 (75 %)
PCI 56 (70 %)
CABG 25 (31 %)
SD standard deviation, BMI body mass index, EF ejection fraction,
CAD coronary artery disease, PCI percutaneous coronary intervention,
CABG coronary artery bypass grafting
Table 3 Visual regional prediction of scar using a threshold of 50 %
FDG uptake
Region Sensitivity Specificity PPV NPV
Anterior 50 % (15–85) 97 % (91–99) 50 % (15–85) 97 % (91–99)
Apical 90 % (74–96) 98 % (90–100) 96 % (82–100) 94 % (85–99)
Septal 71 % (47–87) 94 % (85–98) 75 % (51–90) 92 % (83–97)
Lateral 67 % (30–90) 96 % (89–99) 57 % (25–84) 97 % (91–99)
Inferior 56 % (33–77) 100 % (94–100) 100 % (70–100) 90 % (81–95)
Values in parentheses indicate 95 % confidence interval
PPV positive predictive value, NPV negative predictive value
Table 2 Regional mean LV myocardial HU prediction of scar using a
threshold of 50 % FDG uptake
Region FDG scar FDG viable p value
HU n HU n
Anterior 10±31 4 41±11 76 0.03
Apical −9±19 29 39±10 51 < 0.001
Septal 3±32 17 39±13 63 < 0.001
Lateral 2±27 6 40±11 74 < 0.001
Inferior 6±38 16 42±10 64 < 0.001
Mean −2±28 72 40±11 328 < 0.001
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CTscanner (Discovery HD 750, GE Healthcare) during inspi-
ration breath-hold using the following parameters: detector
coverage 40 mm, slice thickness 2.5 mm, rotation time
0.35 s, tube voltage of 120 kV and tube current of 200 mA.
CT images were reconstructed with 5.0 mm section thickness
by using a reconstruction algorithm with a 512×512 matrix.
These reconstructed images were transferred to a dedicated
workstation (AW 4.4 or AW 4.6 GE Healthcare) for further
analysis. Using multiplanar reconstructions of axial horizontal
images, long- and short-axis views were used to evaluate 5 LV
regions, i.e. anterior, apical, septal, lateral and inferior LV wall
from base to apex as described for FDG analysis to ensure
meaningful comparison of the two techniques. Hypodense
regions of the LV myocardium were visually identified and
mean Hounsfield units (HU) of normal and hypodense areas
were measured in anterior, apical, septal, lateral and inferior
wall of LV myocardium. A standard region of interest (ROI)
of 1 cm2 was used for LV myocardium. For areas with small
hypoattenuation, a smaller ROI was used as previously de-
scribed by Gupta et al. [11].
Two blinded independent nuclear cardiologists assessed
interobserver variability using Spearman’s correlation and
Bland-Altman’s analysis in 100 regions from a subset of 20
patients who were randomly selected.
Statistical analysis
The statistical software package SPSS 20.0 (SPSS, Chicago,
IL, USA) was used for analysis. Quantitative variables were
Fig. 1 Horizontal axis view of unenhanced CT (a) and FDG PET (b)
demonstrating a thin subendocardial apical hypodense region of LV
myocardium (black arrows) in unenhanced CT (a) and a nonviable
apical defect in FDG PET (b). Fusion of FDG PET and non-contrast
CT demonstrates a good correlation of apical nonviable defect in FDG
and hypodense LV myocardial region (c)
Fig. 2 Scatter plot showing distribution of HU and FDG uptake
among 400 myocardial regions. The horizontal line at 28.8 HU denotes
the cutoff derived from ROC analysis, and the vertical line at 50 %
uptake denotes the standard of reference for FDG PET. Note that the
majority of dots are located in the lower left or upper right corner, e.g.
true-positive (n068) or true-negative (n0294)
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expressed as mean ± standard deviation (SD) and categori-
cal variables as frequencies or percentages. The diagnostic
performance of hypodense regions as well as the cutoff
threshold values of HU for optional identification of nonvi-
able scar tissue was assessed with a receiver-operating char-
acteristic (ROC) curve analysis. Sensitivity, specificity,
positive predictive value (PPV), negative predictive value
(NPV) and the area under the curve (AUC) of hypodense
regions compared to the reference standard were calculated.
Differences between groups were assessed, using the chi-
square test for categorical variables and Mann–Whitney U
test for continuous variables. A p value <0.05 was consid-
ered statistically significant.
Results
Patient characteristics
All 80 patients had angiographically documented CAD, 60
(75 %) had a history of myocardial infarction (MI), 56 (70 %)
a history of percutaneous coronary intervention (PCI) and 25
(31 %) had undergone coronary artery bybass graft surgery
(CABG). Patient characteristics are given in Table 1.
FDG PET and unenhanced CT analysis
A total of 5×80 regions were successfully analysed. FDG
uptake was <50 % in 72 regions of 48 patients. Mean HU of
LV myocardium in regions with FDG uptake <50 % vs
≥50 % were −2±28 HU vs 40±11 HU (p<0.001). Details
are shown in Tables 2 and 3. The mean HU was comparable
(p 0 NS) in patients with conservative treatment (−1.9±
17.9, n019), PCI only (−2.7±25.6, n036) and revasculari-
zation by CABG or CABG plus PCI (0.6±37.8, n025).
Visual analysis of unenhanced CT identified 63 hypo-
dense regions in 45 patients resulting in a sensitivity of 74 %
[confidence interval (CI) 62–83 %], specificity of 97 % (CI
94–99 %), PPVof 84 % (CI 73–92 %) and NPVof 94 % (CI
91–97 %) to detect nonviable LV myocardium using a
threshold of 50 % (Fig. 1).
The ROC analysis of the quantitative analysis revealed a
cutoff value of <28.8 HU for detecting nonviable tissue
(<50 % FDG uptake) with an AUC of 0.93. Using the
threshold of 28.8 HU, unenhanced CT identified 102 non-
viable regions in 56 patients (Fig. 2), yielding a sensitivity
of 94 % (CI 86–98 %), specificity of 90 % (CI 86–93 %),
PPV of 67 % (CI 57–76 %) and NPV of 99 % (CI 97–
100 %), respectively. The respective values for all FDG
uptake thresholds depicting scar (i.e. <30, <40, <50 and
<60 %) are summarized in Tables 4 and 5 and illustrated
in Fig. 3.
Interobserver variability of CT density measurements
was obtained in a subgroup of 100 regions by independent
review of two blinded observers. Spearman’s correlation
revealed an excellent correlation coefficient (r00.93, p<
0.001) and Bland-Altman’s analysis documents narrow lim-
its of agreement (−11.95 to 12.92 HU; Fig. 4).
The mean effective radiation dose from FDG was 5.02±
0.03 mSv (calculated from 251±16.3 MBq times the con-
version factor 0.02 mSv/MBq [20]) and 0.9±0.1 mSv for
unenhanced CT.
Table 4 Global accuracy of visual analysis in unenhanced CT to predict myocardial scar using different FDG thresholds
FDG threshold Sensitivity Specificity PPV NPV
< 30 % 93 % (70–99) 87 % (84–90) 22 % (14–34) 100 % (98–100)
< 40 % 86 % (72–94) 91 % (88–94) 51 % (39–63) 99 % (97–100)
< 50 % 74 % (62–83) 97 % (94–99) 84 % (73–92) 94 % (91–97)
< 60 % 42 % (34–50) 98 % (96–99) 94 % (85–98) 75 % (71–80)
Values in parentheses indicate 95 % confidence interval
PPV positive predictive value, NPV negative predictive value
Table 5 Global accuracy of quantitative hypodense area analysis in unenhanced CT to predict myocardial scar using different FDG thresholds
FDG threshold Sensitivity Specificity PPV NPV AUC Cutoff
< 30 % 93 % (70–99) 91 % (87–93) 28 % (18–41) 100 % (98–100) 0.95 <7.9 HU
< 40 % 95 % (82–98) 91 % (88–94) 51 % (40–63) 99 % (98–100) 0.97 <19.1 HU
< 50 % 94 % (86–98) 90 % (86–93) 67 % (57–76) 99 % (97–100) 0.93 <28.8 HU
< 60 % 62 % (54–70) 93 % (90–96) 84 % (76–90) 82 % (77–86) 0.78 <29.2 HU
Values in parentheses indicate 95 % confidence interval
PPV positive predictive value, NPV negative predictive value, AUC area under the curve
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Discussion
The present results demonstrate that hypodense areas in
unenhanced cardiac CT allow accurate identification of non-
viable scar tissue as it shows excellent agreement with
reduced myocardial FDG uptake. While contrast-enhanced
CT angiography has been shown to accurately detect fixed
perfusion defects or scar as areas of late enhancement com-
paring well to MPI or cardiac magnetic resonance, no firm
data on unenhanced CT are available using an established
gold standard for viability. Our report is the first validation
study documenting the accuracy of unenhanced cardiac CT
for identifying nonviable myocardial scar using the well-
established metabolic marker FDG. Preliminary studies
have suggested that after MI the process of ventricular
remodelling including rarefaction due to fatty replacement
and reduced capillary density may lead to hypoattenuation
in unenhanced cardiac CT [21] and may be related to de-
velopment of severe heart failure.
We have determined the optimal cutoff value for detec-
tion of myocardial scar as <28.8 HU, yielding a sensitivity
of 94 % and a specificity of 90 % with an excellent inter-
observer agreement (r00.93, p<0.001). The latter is impor-
tant in order to allow widespread use in routine clinical
practice, where unenhanced cardiac CT scans are increas-
ingly being used for coronary calcium scoring and/or atten-
uation correction of nuclear myocardial imaging.
Although several noninvasive cardiac imaging modalities
have been suggested for evaluation of viable myocardium,
including cardiac MRI [15], low-dose dobutamine stress
echocardiography [22] and SPECT [23], FDG PET has
remained the gold standard and is the only technique
evaluated in a prospective randomized outcome trial [24].
Interestingly, the findings of the present study remained
consistent when using the most widely accepted thresholds
of <40 % and <50 % for FDG uptake defining scar.
Accurate assessment of clinically silent MI is important
for effective management as the cardiovascular event rate is
as high as after clinically overt MI (45–55 % 10-year mor-
tality) [25, 26]. Hence, any methodological improvement for
accurate MI detection is welcome, albeit its impact on
patients’ outcome will require further prospective testing.
The results of the present study suggest that, besides calcium
scoring, unenhanced cardiac CTscans may be used for detecting
nonviablemyocardial scars. In patients undergoing nuclearMPI,
findings of hypodense regions may confer an added value in
discriminating MI from attenuation artefact. In cases of known
MI the choice of treatment strategy may rely on the accurate
depiction or exclusion of viable tissue in the defect territory.
Interestingly, on the one hand, sensitivity of visual CT
analysis was lower compared to the quantitative analysis. This
suggests that a lower visual threshold dominates the subjective
Fig. 3 The ROC analysis of the quantitative HU measurement
revealed cutoff values at <7.9, <19.1, <28.8 and <29.2 HU for detect-
ing myocardial tissue <30, <40, <50 and <60 % FDG uptake with an
AUC of 0.95, 0.97, 0.93 and 0.78
Fig. 4 Interobserver analysis of
the mean regional HU from 100
myocardial regions in 20
patients. Spearman’s correlation
reveals an excellent correlation
coefficient (r00.93, p<0.001,
left panel) and Bland-Altman’s
analysis documents narrow
limits of agreement (right
panel)
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interpretation of lower attenuation myocardial areas compared
to the quantitative measurement of CT density units. On the
other hand, the PPVof visual analysis was higher. Hence, in the
presence of visible hypodense myocardial LV areas the preva-
lence of myocardial viability is exceedingly rare and therefore
these regions are unlikely to benefit from revascularization
procedures. The highest sensitivity of unenhanced CT to detect
scar tissue was found in the apex. This could be attributed to the
fact that in the study population the prevalence of scar was
highest in the apex, where scar was located in two thirds of
patients with any scar. In addition, the HU values were lowest
in the apex, possibly indicating more transmurality of apical
infarction, translating into better detectability.
It may be perceived as a potential limitation of this study that
neither a glucose-insulin clamp nor acipimox was used to
optimize the myocardial FDG uptake. However, the oral glu-
cose load method with insulin adjustments if needed is widely
used and well established [27, 28]. Further, we used a 5-
segment model of the polar plots of FDG instead of the classic
17-segment model. However, this was chosen to allow mean-
ingful comparison with the unenhanced CT. The latter would
not have allowed reliable segmentation of the left ventricle into
17 segments due to the lack of contrast signal. Moreover, in this
validation study the prevalence of patients with MI was rela-
tively high, while this may be lower in a population undergoing
calcium scoring or evaluation of ischaemia with SPECT MPI.
Indeed, lower prevalence would result in an even higher NPV to
rule out nonviable tissue, which further strengthens our data.
Finally, we did not use MPI to normalize FDG uptake. How-
ever, this is in line with the evidence from many studies show-
ing that viability is best characterized by FDG uptake, while the
diagnostic role of perfusion has remained controversial [29].
In conclusion, hypodense areas in unenhanced CT accurate-
ly detect nonviable LV myocardial regions as defined by FDG
PET. In patients undergoing a CT scan for calcium scoring or
for attenuation correction of nuclear MPI this may confer an
added value for optimal subsequent patient management.
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